Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A1 | P04798 | 4/20 | 0.46 |
| ▸ | CYP1B1 | Q16678 | 4/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.46 |
| ▸ | NFE2L2 | Q16236 | 2/20 | 0.44 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.44 |
| ▸ | TUBB1 | Q9H4B7 | 2/20 | 0.41 |
| ▸ | ESR1 | P03372 | 1/20 | 0.41 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.40 |
| ▸ | TUBB4A | P04350 | 1/20 | 0.40 |
| ▸ | TUBB | P07437 | 1/20 | 0.40 |
| ▸ | TUBA3C | P0DPH7 | 1/20 | 0.40 |
| ▸ | TUBA1B | P68363 | 1/20 | 0.40 |
| ▸ | TUBA4A | P68366 | 1/20 | 0.40 |
| ▸ | TUBB4B | P68371 | 1/20 | 0.40 |
| ▸ | TUBB3 | Q13509 | 1/20 | 0.40 |
| ▸ | TUBB2A | Q13885 | 1/20 | 0.40 |
| ▸ | TUBB8 | Q3ZCM7 | 1/20 | 0.40 |
| ▸ | TUBA3E | Q6PEY2 | 1/20 | 0.40 |
| ▸ | TUBA1A | Q71U36 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4924654 | 1.00 | CYP1A1 (0.46) | CYP1A1CYP1B1CYP1A2NFE2L2TRPA1 | |
| SCHEMBL4931971 | 0.84 | ALDH1A1 (0.45) | ESR1ESR2MAPTLMNAMEN1 | |
| SCHEMBL4931049 | 0.78 | ESR1 (0.48) | ESR1ESR2MAPTMEN1KMT2A | |
| SCHEMBL4600907 | 0.77 | ESR1 (0.46) | NFE2L2TRPA1ESR1ESR2MAPT | |
| SCHEMBL4925484 | 0.75 | KDM4E (0.48) | ESR1ESR2MAPTLMNAMEN1 | |
| SCHEMBL4931003 | 0.74 | ESR1 (0.44) | ESR1ESR2MAPTLMNAMEN1 | |
| SCHEMBL19583347 | 0.73 | NFE2L2 (0.71) | CYP1A1CYP1B1CYP1A2NFE2L2TRPA1 | |
| SCHEMBL19583346 | 0.73 | NFE2L2 (0.71) | CYP1A1CYP1B1CYP1A2NFE2L2TRPA1 | |
| SCHEMBL4931993 | 0.73 | ESR1 (0.41) | ESR1ESR2MAPTLMNA | |
| SCHEMBL4933053 | 0.73 | ESR1 (0.41) | ESR1ESR2MAPTPDGFRBPDGFRA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080070960-A1 | Novel 3-Aryl-1,2-Benzisoxazole Derivatives and Use Thereof as Medicinal Products Against Cancer | AVENTIS PHARMA S.A. (FR) | 2008-03-20 | — | — | US | disclosed |
| EP-1861381-A1 | NOVEL 3-ARYL-1,2-BENZISOXAZOLE DERIVATIVES, COMPOSTIONS CONTAINING SAME AND USE THEREOF | Aventis Pharma S.A. (FR) | 2007-12-05 | — | — | EP | disclosed |
| WO-2006090052-A1 | NOVEL 3-ARYL-1,2-BENZISOXAZOLE DERIVATIVES, COMPOSITIONS CONTAINING SAME AND USE THEREOF | AVENTIS PHARMA S.A. (FR) | 2006-08-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080070960-A1 | Novel 3-Aryl-1,2-Benzisoxazole Derivatives and Use Thereof as Medicinal Products Against Cancer | UGT2B7, UGT2B17, CYP4X1 | CYP1A1 19/4885CYP1B1 14/4885CYP1A2 13/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.